[EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:VIIV HEALTHCARE UK NO 5 LTD
公开号:WO2020095176A1
公开(公告)日:2020-05-14
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
化合物及其药用可接受的盐,以及用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法被阐明。
[EN] DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES<br/>[FR] DÉRIVÉS D'AMIDES D'ACIDE 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-CARBOXYLIQUE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2010141273A1
公开(公告)日:2010-12-09
Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
Directed C–C bond cleavage of a cyclopropane intermediate generated from<i>N</i>-tosylhydrazones and stable enaminones: expedient synthesis of functionalized 1,4-ketoaldehydes
-quaternary centers via regioseletive C-C bond activation has been described. Through cyclopropanation of bench-stable enaminones with in situ generated diazo reagents from N-tosylhydrazones, followed by selective C-C bond cleavage of the cyclopropane ring affords the 1, 4-ketoaldehyde derivatives in good to excellent yields. This method works with broad substrate scope and high regioseletivity.
A highly site-selective acyloxylation of stable enamines with PhI(OAc)2 under metal-free conditions to afford (E)-vinyl acetate derivatives in good to excellent yields is described. Depending on the judicious choice of the solvent system, either the α- or β-site-selective product could be obtained with high selectivity. For the α-site-selective product, the rearranged amide compound is obtained as
[EN] AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS<br/>[FR] AZABENZIMIDAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DES RÉCEPTEURS AMPA
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2016176460A1
公开(公告)日:2016-11-03
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [formula (I) should be inserted here]. Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).